

Kimberly-Clark

Q4 results soft, 2024 focus on volume recovery; Reiterate Underperform

Reiterate Rating: UNDERPERFORM | PO: 110.00 USD | Price: 118.04 USD

Q4 organic sales in-line but volume light on recovery

Q4 results EPS of \$1.51 was slightly ahead of our \$1.50 but missed the Street's \$1.53 as organic sales came in consistent with expectations but total company volumes were flattish vs. our expectation of +1% growth. The personal care segment saw its second sequential quarter of volume growth, at +1%, while the Consumer Tissue (-1%) and K-C Professional (-4%) segments moderated volume weakness.

Gross margin declines from Q3's peak; market share soft

Gross margin expanded +220bps y/y to 34.9%, but was below Q3's level of 35.8%, although a sequential step down was expected as pricing waned. In 2024, we see the gross margin landscape as less certain due to possible impacts of higher oil prices on raw material inputs, while KMB also noted higher distribution and labor costs along with currency headwinds. Meanwhile, market share of ~40% is below the company's goal of 50% or more on a cohort basis. Market share was partially affected by supply constraints in North America in 2023, which underperformed markets such as South Korea, Australia & New Zealand, and China where KMB saw varying levels of market share gains.

2024 guidance introduced; lowering estimates

KMB introduced 2024 guidance, with organic sales expected to increase +LSD to +MSD, with net sales offset by -300bps of currency headwind and -60% from the Brazil divestiture. Organic sales growth is expected to be balanced through the year but softer in Q1 due to more muted volume growth. We expect margins to be relatively steady although we note downside risk on shipping and commodity inputs due to the Red Sea conflict. Overall, we lower our Q1 EPS estimate to \$1.59 from \$1.76 prior and lower our 2024E EPS estimate to \$6.71 from \$6.91 prior. KMB plans to host an Investor Day in March to discuss its long-term outlook and strategy.

Reiterate Underperform, lowering PO to \$110 from \$115

We reiterate our Underperform rating and lower our PO to \$110 from \$115, reflecting a ~16x multiple on our CY25e EPS of \$7.06. We see a challenging setup ahead due to a potentially farther out recovery in volumes while pricing benefits wane, and softness in market share, offset by input cost benefits and cost savings.

Estimates (Dec) (US\$)	2022A	2023A	2024E	2025E	2026E
EPS	5.63	6.57	6.71	7.06	7.48
GAAP EPS	5.72	5.21	6.71	7.06	7.48
EPS Change (YoY)	-8.9%	16.7%	2.1%	5.2%	5.9%
Consensus EPS (Bloomberg)			7.02	7.47	7.84
DPS	4.62	4.70	4.84	5.00	5.16
Valuation (Dec)					
P/E	21.0x	18.0x	17.6x	16.7x	15.8x
GAAP P/E	20.6x	22.7x	17.6x	16.7x	15.8x
Dividend Yield	3.9%	4.0%	4.1%	4.2%	4.4%
EV / EBITDA*	14.1x	12.8x	12.1x	11.9x	11.5x
Free Cash Flow Yield*	4.7%	7.0%	5.8%	5.7%	5.9%
* For full definitions of <i>iQ</i> method SM measures, see page 5.					

BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Refer to important disclosures on page 6 to 8. Analyst Certification on page 4. Price
Objective Basis/Risk on page 4.

24 January 2024

Equity

Key Changes		
(US\$)	Previous	Current
Price Obj.	115.00	110.00
2024E Rev (m)	21,039.4	20,661.4
2025E Rev (m)	21,362.8	20,978.0
2026E Rev (m)	NA	21,300.1
2024E EPS	6.91	6.71
2025E EPS	7.23	7.06
2026E EPS	NA	7.48

Anna Lizzul

Research Analyst BofAS

+1 646 855 2569 anna.lizzul@bofa.com

Bryan D. Spillane

Research Analyst BofAS

+1 646 855 1979 bryan.spillane@bofa.com

Jonathan Keypour

Research Analyst

+1 646 855 4345

jonathan.keypour@bofa.com

Stock Data

Price	118.04 USD
Price Objective	110.00 USD
Date Established	24-Jan-2024
Investment Opinion	A-3-7
52-Week Range	116.32 USD - 147.87 USD
Mrkt Val (mn) / Shares Out	39,768 USD / 336.9
(mn)	
Free Float	99.9%
Average Daily Value (mn)	231.51 USD
BofA Ticker / Exchange	KMB / NYS
Bloomberg / Reuters	KMB US / KMB.N
ROE (2024E)	245.5%
Net Dbt to Eqty (Dec-2023A)	NA
ESGMeter™	High

ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of BofA Global Research's equity investment rating, volatility risk rating, income rating, and price objective for that company. For full details, refer to "BofA ESGMeter Methodology".

iQprofile[™] Kimberly-Clark

iQmethod SM − Bus Performance*					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Return on Capital Employed	18.0%	20.9%	21.8%	22.1%	22.7%
Return on Equity	359.1%	299.3%	245.5%	260.5%	229.6%
Operating Margin	13.0%	14.5%	15.2%	15.4%	15.6%
Free Cash Flow	1,857	2,776	2,315	2,284	2,359
<i>iQ</i> method [™] – Quality of Earnings*					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Cash Realization Ratio	1.4x	1.6x	1.5x	1.4x	1.4x
Asset Replacement Ratio	1.2x	1.0x	1.3x	1.3x	1.3x
Tax Rate	21.2%	22.4%	24.0%	24.0%	24.0%
Net Debt-to-Equity Ratio	NM	NM	NM	NM	NM
Interest Cover	9.3x	10.1x	10.4x	11.7x	13.0x
Income Statement Data (Dec)					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Sales	20,175	20,431	20,661	20,978	21,300
% Change	3.8%	1.3%	1.1%	1.5%	1.5%
Gross Profit	6,219	7,047	7,220	7,350	7,568
% Change	1.3%	13.3%	2.5%	1.8%	3.0%
EBITDA	3,371	3,711	3,915	4,007	4,124
% Change	-6.4%	10.1%	5.5%	2.3%	2.9%
Net Interest & Other Income	(289)	(288)	(325)	(311)	(292)
Net Income (Adjusted) % Change	1,905 -9.1%	2,227 16.9%	2,249 1.0%	2,321 3.2%	2,415 4.1%
·					
Free Cash Flow Data (Dec)					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Net Income from Cont Operations (GAAP)	1,935	1,765	2,249	2,322	2,416
Depreciation & Amortization	754	753	768	783	799
Change in Working Capital	(17)	582	(16)	29	9
Deferred Taxation Charge	(57)	(322)	(126)	0	0
Other Adjustments, Net	118	764	422	147	148
Capital Expenditure Free Cash Flow	(876)	(766)	(982) 2,315	(997)	(1,013)
% Change	1,857 7.8%	2,776 49.5%	-16.6%	2,284 -1.4%	2,359 3.3%
Share / Issue Repurchase	(6)	(128)	(700)	(700)	(700)
Cost of Dividends Paid	(1,558)	(1,588)	(1,622)	(1,644)	(1,666)
Change in Debt	(51)	(483)	(1,022)	(75)	(100)
	(= 1)	(102)	(**==)	(/	(122)
Balance Sheet Data (Dec)	20224	20224	20245	20255	20265
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Cash & Equivalents	427	1,093	986	986	743
Trade Receivables Other Current Assets	2,280	2,135 2,475	2,208	2,208	2,276
Property, Plant & Equipment	3,022 7,885	7,913	2,441	2,441	2,481 8,675
Other Non-Current Assets	4,356	3,728	8,167 3,688	8,167 3,688	
Total Assets		3,728 17,344		,	3,608
Short-Term Debt	17,970 844	1 7,344 567	17,490 567	17,490 567	17,783 567
Other Current Liabilities	6,490	6,363	6,386	6,386	6,532
Long-Term Debt	7,578	7,417	7,317	7,317	7,142
Other Non-Current Liabilities	2,511	1,929	2,329	2,329	2,329
Total Liabilities	17,423	16,276	16,599	16,599	16,570
Total Equity	547	941	891	891	1,213
Total Equity Total Equity & Liabilities	17,970	17,217	17,490	17,490	17,783
* For full definitions of IOmethod SM measures see page 5	17,570	17,217	17,430	17,430	17,703

Company Sector

Household Products

Company Description

Kimberly-Clark (KMB) is a global health and hygiene company which sells consumer products. The company manufactures products including diapers, tissues, paper towels, incontinence care products, and feminine hygiene products. Global brands include: Huggies, Pull-Ups, Kotex, Kleenex, Cottonelle, Viva, Scott, Depend, and Poise. Approximately 50% of sales are derived outside of North America.

Investment Rationale

We rate KMB shares Underperform. We appreciate that KMB is beginning to execute on its dual-pronged growth strategy to: 1) elevate the core business, and 2) expand into high-growth developing markets. We see risk to the downside due to global declining birth rates, elevated commodity costs, and a potential economic downturn hurting share and premiumization mix across categories. Meanwhile, pricing actions are expected to abate, providing more limited upside to gross margin expansion.

Stock Data

Average Daily Volume

1,961,299

Quarterly Earnings Estimates

	2023	2024
Q1	1.67A	1.59E
Q2	1.65A	1.61E
Q3	1.74A	1.81E
04	1.51A	1.70E



* For full definitions of $\emph{\textbf{IQ}}\textit{method}^{\,\text{SM}}$ measures, see page 5.

Exhibit 1: KMB Income Statement: Q4 results EPS of \$1.51 was slightly ahead of our \$1.50 Fiscal year end December; \$ in millions, except for per share data

			2023A					2024E		
	Mar-23	Jun-23	Sep-23	Dec-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Dec-24
Net Calca	Q1	Q2 CF 134	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
Net Sales	\$5,195 2.0%	\$5,134 1.4%	\$5,132 1.6%	\$4,970 0.1%	\$20,431 1.3%	\$5,090 -2.0%	\$5,157 0.4%	\$5,244	\$5,171 4.1%	\$20,661 1.1%
growth	2.0% 2,704	1. 4% 2,685	2,700	2,602				2.2% 2,754	4.1% 2,732	10,807
Personal Care			2,700		10,691	2,623 -3.0%	2,698		2,732 5.0%	
growth	-0.9% 1,634	-0.9% 1,549	2.7% 1,567	1.8% 1,540	0.6% 6,290	-3.0% 1,618	0.5% 1,549	2.0% 1,598	1,586	1.1% 6,351
Consumer Tissue	4.2%	0.8%	-0.7%	-1.3%	0.8%	-1.0%	0.0%	2.0%	3.0%	1.0%
growth K-C Professional & Other	847	887	854	816	3,404	839	896	880	840	
	8.6%	10.6%	2.2%	-2.6%	3,404 4.5%	-1.0%	1.0%	3.0%	3.0%	3,455 1.5%
growth	10	13	2.2%	-2.0% 12	4.5%	-1.0%	1.0%	3.0%	3.0%	48
Intersegment Cost of Goods Sold - reported	3,469	3,403	3,294	3,233	13,399	3,329	3,374	3,387	3,351	13,442
Cost of Goods Sold	3,469	3,388	3,294	3,233	13,384	3,329	3,374	3,387	3,351	13,442
Gross Profit - reported	1,726	1,731	1,838	1,737	7,032	1,761	1,783	1,856	1,820	7,220
Gross Profit	1,726	1,731	1,838	1,737	7,032 7,047	1,761	1,783	1,856	1,820	7,220
Gross Margin- reported	33.2%	33.7%	35.8%	34.9%	34.4%	34.6%	34.6%	35.4%	35.2%	34.9%
y/y chg	339	352	528	217	359	137	86	(42)	24	52
Gross Margin	33.2%	34.0%	35.8%	34.9%	34.5%	34.6%	34.6%	35.4%	35.2%	34.9%
y/y chg	33.2%	381	528	217	367	137	5 4 .0%	(42)	24	45
Marketing, research, g&a - reported	924	1,015	1,029	993	3,961	997	994	1,015	997	4,003
Marketing, research, g&a	924	1,013	1,029	993	3,946	997	994	1,015	997	4,003
as % of sales	17.8%	19.5%	20.1%	20.0%	19.3%	19.6%	19.3%	19.4%	19.3%	19.4%
y/y chg	81	15.5%	20.1%	153	167	180	(20)	(70)	(70)	1 3.4 70
Other (income) expense, net - reported	15	603	35	74	727	18	18	18	18	70
Other (income) expense, net	15	19	35	74	143	18	18	18	18	70
Operating Income - reported	787	113	774	670	2,344	746	771	824	805	3,147
Operating Income	787 787	727	774	670	2,958	746	771	824	805	3,147
Operating Margin	15.1%	14.2%	15.1%	13.5%	14.5%	14.7%	15.0%	15.7%	15.6%	15.2%
y/y chg	280	190	212	(86)	151	(49)	80	63	209	75
Nonoperating Expense - reported	(16)	(42)	(20)	(18)	(96)	(12)	(12)	(12)	(12)	(48)
Nonoperating Expense	(16)	(15)	(16)	(14)	(61)	(12)	(12)	(12)	(12)	(48)
Interest Income	7	9	18	32	66	6	6	6	6	24
Interest Expense	(73)	(76)	(74)	(70)	(293)	(76)	(75)	(75)	(75)	(301)
Pretax Income - reported	705	4	698	614	2,021	664	690	743	724	2,822
Pretax Income	705	645	702	618	2,670	664	690	743	724	2,822
Pretax Margin	13.6%	12.6%	13.7%	12.4%	13.1%	13.1%	13.4%	14.2%	14.0%	13.7%
Income Taxes - reported	173	(32)	157	155	453	159	166	178	174	677
Income Taxes	173	132	158	156	619	159	166	178	174	677
Tax Rate - reported	24.5%	-800.0%	22.5%	25.2%	22.4%	24.0%	24.0%	24.0%	24.0%	24.0%
Tax Rate - ex-charges	24.5%	20.5%	22.5%	25.2%	23.2%	24.0%	24.0%	24.0%	24.0%	24.0%
Income before Equity Interests	\$532	\$513	\$544	\$462	\$2,051	\$505	\$524	\$564	\$551	\$2,144
Share of net income of equity companies - reported	43	50	50	53	196	44	30	52	27	153
Share of net income of equity companies	43	50	50	53	196	44	30	52	27	153
Minority Interest - reported	(9)	16	(4)	(3)	0	(12)	(12)	(12)	(12)	(48)
Minority Interest	(9)	(4)	(4)	(3)	(20)	(12)	(12)	(12)	(12)	(48)
Net Income	\$566	\$559	\$590	\$512	\$2,227	\$537	\$542	\$604	\$566	\$2,249
Restructuring and other	0	477	3	3	483	0	0	0	0	0
GAAP Net Income - Diluted	566	102	587	509	1,764	537	542	604	566	2,249
Diluted EPS - continuing operations										
EPS - ex-charges	\$1.67	\$1.65	\$1.74	\$1.51	\$6.57	\$1.59	\$1.61	\$1.81	\$1.70	\$6.71
GAAP EPS - Diluted	\$1.67	\$0.30	\$1.73	\$1.50	\$5.21	\$1.59	\$1.61	\$1.81	\$1.70	\$6.71
Diluted Shares outstanding	338.2	338.9	338.9	339.0	338.8	337.6	336.0	334.3	332.7	335.2
C										

Source: Company reports and BofA Global Research estimates.

BofA GLOBAL RESEARCH



Price objective basis & risk

Kimberly-Clark (KMB)

Our \$110 price objective is based on a CY25e P/E ratio of 16x, a discount to the company's 10-year average P/E multiple, due to a longer-term recovery in volumes and market share. On an absolute and relative basis vs. HPC peers, KMB trades below its 2-year forward P/E average of appx. 18x. We see a potentially difficult setup ahead, with current valuation justified by limited organic sales growth on weak volumes as pricing benefits wane, and tempered expectations on gross margin expansion ahead due to input volatility, partially offset by cost savings.

Upside risks to our price objective are: 1) global rising birth rates, 2) continued elevation of brands with accelerated market share gains in developing and D&E markets, 3) a better than expected consumer environment leading to higher mix of premium products, 4) pricing actions and cost savings more than offset cost inflation, 5) key commodity costs abate.

Downside risks to our price objective are: 1) global declines in birth rates accelerate, 2) erosion in market share due to a challenging consumer environment, 3) difficulty implementing pricing and cost savings initiatives, 4) cost inflation continues to rise in key commodity costs, hampering gross margins.

Analyst Certification

I, Anna Lizzul, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

US - Consumables Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
BUY				
	BellRing Brands Inc	BRBR	BRBR US	Bryan D. Spillane
	Coca-Cola Europacific Partners plc	CCEP	CCEP US	Bryan D. Spillane
	Colgate-Palmolive Company	CL	CL US	Bryan D. Spillane
	Constellation Brands	STZ	STZ US	Bryan D. Spillane
	Coty Inc.	COTY	COTY US	Anna Lizzul
	e.l.f. Beauty	ELF	ELF US	Anna Lizzul
	Freshpet, Inc.	FRPT	FRPT US	Bryan D. Spillane
	Kenvue Inc.	KVUE	KVUE US	Anna Lizzul
	Keurig Dr Pepper	KDP	KDP US	Bryan D. Spillane
	Kraft Heinz Company	KHC	KHC US	Bryan D. Spillane
	Lamb Weston Holdings Inc	LW	LW US	Peter T. Galbo, CFA
	McCormick & Co.	MKC	MKC US	Peter T. Galbo, CFA
	Mondelez International	MDLZ	MDLZ US	Bryan D. Spillane
	Monster Beverage Corporation	MNST	MNST US	Peter T. Galbo, CFA
	PepsiCo	PEP	PEP US	Bryan D. Spillane
	Philip Morris International	PM	PM US	Lisa K. Lewandowski
	Pilgrim's Pride Corp.	PPC	PPC US	Peter T. Galbo, CFA
	The Coca Cola Company	KO	KO US	Bryan D. Spillane
	The Procter & Gamble Company	PG	PG US	Bryan D. Spillane
NEUTRAL				
	Altria Group	MO	MO US	Lisa K. Lewandowski
	Celsius Holdings Inc	CELH	CELH US	Jonathan Keypour
	Church & Dwight	CHD	CHD US	Anna Lizzul
	Clorox	CLX	CLX US	Anna Lizzul
	Conagra Brands, Inc.	CAG	CAG US	Peter T. Galbo, CFA
	Estee Lauder Companies Inc.	EL	EL US	Bryan D. Spillane
	General Mills	GIS	GIS US	Bryan D. Spillane



US - Consumables Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	JM Smucker Company	SJM	SJM US	Peter T. Galbo, CFA
	Kellanova	K	K US	Peter T. Galbo, CFA
	Molson Coors Beverage Company	TAP	TAP US	Bryan D. Spillane
	The Duckhorn Portfolio, Inc.	NAPA	NAPA US	Peter T. Galbo, CFA
	The Hershey Company	HSY	HSY US	Bryan D. Spillane
	Utz Brands	UTZ	UTZ US	Peter T. Galbo, CFA
	WK Kellogg Co	KLG	KLG US	Peter T. Galbo, CFA
UNDERPERFORM				
	Brown-Forman Corporation	BFB	BF/B US	Bryan D. Spillane
	Campbell Soup Company	CPB	CPB US	Peter T. Galbo, CFA
	Canopy Growth	YWEED	WEED CN	Lisa K. Lewandowski
	Canopy Growth	CGC	CGC US	Lisa K. Lewandowski
	Cronos Group	YCRON	CRON CN	Lisa K. Lewandowski
	Cronos Group	CRON	CRON US	Lisa K. Lewandowski
	Dole plc	DOLE	DOLE US	Bryan D. Spillane
	Herbalife Nutrition Ltd	HLF	HLF US	Anna Lizzul
	Hormel Foods Corp.	HRL	HRL US	Peter T. Galbo, CFA
	Kimberly-Clark	KMB	KMB US	Anna Lizzul
	Tyson Foods, Inc.	TSN	TSN US	Peter T. Galbo, CFA
RSTR				
	The Vita Coco Company, Inc.	COCO	COCO US	Bryan D. Spillane

*Q*method[™] Measures Definitions

Numerator

Business Performance

Return On Capital Employed	NOPAT = (EBIT + Interest Income) \times (1 $-$ Tax Rate) + Goodwill Amortization	Total Assets — Current Liabilities + ST Debt + Accumulated Goodwill Amortization
Poturn On Fauity	Net Income	
Return On Equity		Shareholders' Equity
Operating Margin	Operating Profit	Sales
Earnings Growth	Expected 5 Year CAGR From Latest Actual	N/A
Free Cash Flow	Cash Flow From Operations — Total Capex	N/A
Quality of Earnings	Numerator	Denominator
Cash Realization Ratio	Cash Flow From Operations	Net Income
Asset Replacement Ratio	Capex	Depreciation
Tax Rate	Tax Charge	Pre-Tax Income
Net Debt-To-Equity Ratio	Net Debt = Total Debt - Cash & Equivalents	Total Equity
Interest Cover	EBIT	Interest Expense
Valuation Toolkit	Numerator	Denominator
Price / Earnings Ratio	Current Share Price	Diluted Earnings Per Share (Basis As Specified)
Price / Book Value	Current Share Price	Shareholders' Equity / Current Basic Shares
Dividend Yield	Annualised Declared Cash Dividend	Current Share Price
Free Cash Flow Yield	Cash Flow From Operations – Total Capex	Market Cap = Current Share Price × Current Basic Shares
Enterprise Value / Sales	EV = Current Share Price × Current Shares + Minority Equity + Net Debt +	Sales
•	Other LT Liabilities	
EV / EDITOA	Fintage via a Malua	Desig FRIT - Depresiation - Appartmention

Denominator

EV / EBITDA Enterprise Value Basic EBIT + Depreciation + Amortization

Menethod 3*is the set of BofA Global Research standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of iQmethod are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.

Redatabase is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by BofA Global Research.

*IQ*profileSM, *IQ*methodSM are service marks of Bank of America Corporation. *IQ*database[®] is a registered service mark of Bank of America Corporation.



Disclosures

Important Disclosures

Kimberly-Clark (KMB) Price Chart



B: Buy, N: Neutral, U: Underperform, PO: Price Objective, NA: No longer valid, NR: No Rating

The Investment Opinion System is contained at the end of the report under the heading "Fundamental Equity Opinion Key". Dark grey shading indicates the security is restricted with the opinion suspended. Medium grey shading indicates the security is under review with the opinion withdrawn. Light grey shading indicates the security is not covered. Chart is current as of a date no more than one trading day prior to the date of the report.

Equity Investment Rating Distribution: Consumer Products Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships R1	Count	Percent
Buy	32	50.00%	Buy	16	50.00%
Hold	19	29.69%	Hold	8	42.11%
Sell	13	20.31%	Sell	7	53.85%

Equity Investment Rating Distribution: Global Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships R1	Count	Percent
Buy	1895	53.62%	Buy	1083	57.15%
Hold	832	23.54%	Hold	454	54.57%
Sell	807	22.84%	Sell	383	47.46%

R1 Issuers that were investment banking clients of BofA Securities or one of its affiliates within the past 12 months. For purposes of this Investment Rating Distribution, the coverage universe includes only stocks. A stock rated Neutral is included as a Hold, and a stock rated Underperform is included as a Sell.

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating Total return expectation (within 12-month period of date of initial rating) Ratings dispersion guidelines for coverage cluster^{R2}

Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Inderperform	N/A	≥ 20%

R2Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Price Charts for the securities referenced in this research report are available on the Price Charts website, or call 1-800-MERRILL to have them mailed.

BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: Kimberly-Clark.

The issuer is or was, within the last 12 months, an investment banking client of BofAS and/or one or more of its affiliates: Kimberly-Clark.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: Kimberly-Clark

An officer, director or employee of BofAS or one of its affiliates is an officer or director of this issuer. Kimberly-Clark.

BofAS or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer or an affiliate of the issuer within the next three months. Kimberly-

BofAS together with its affiliates beneficially owns one percent or more of the common stock of this issuer. If this report was issued on or after the 9th day of the month, it reflects the ownership position on the last day of the previous month. Reports issued before the 9th day of a month reflect the ownership position at the end of the second month preceding the date of the report: Kimberly-Clark.



BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: Kimberly-Clark.

The issuer is or was, within the last 12 months, a securities business client (non-investment banking) of BofAS and/or one or more of its affiliates: Kimberly-Clark.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.

Other Important Disclosures

From time to time research analysts conduct site visits of covered issuers. BofA Global Research policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments. Refer to BofA Global Research policies relating to conflicts of interest.

"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): Bof regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofASEdisclaimer; BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI, BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch (Australia): Merrill Lynch (Hong Kong): Merrill (Hong Kong): Merr (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaría y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch (Israel): Merrill Lynch (Israel) Merrill Lynch (Israel) Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution or distribution in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and are gulated by the DFSA. Information in Germany and is regulated by Merrill Lynch (DIFC) is done so in accordance with the re

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.



Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions in any securities referred to herein.

BofA ESGMeter Methodology:

ESGMeter is a proprietary metric based on quantitative analysis and fundamental analyst inputs that reflects our assessment of a company's Environmental, Social and Governance-related attributes. The ESGMeter is intended to indicate a company's likelihood of experiencing stronger financial stability (higher return on equity and lower earnings and price volatility) over the next three years relative to peer group. There are three ESGMeter levels - Low, Medium, and High - which indicate whether a company has attributes most likely to translate into superior financial stability (in the case of a High level) or weaker financial stability (in the case of a Low level) over the next three years relative to its peer group. A Medium level suggests that a company exhibits ESG characteristics that are likely associated with financial stability results in line with its peer group over the next three years. Full details of our methodology, financial stability definition and disclaimers are available at BofA ESGMeter methodology. ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of the BofA Global Research fundamental equity analyst's investment rating, volatility risk rating, income rating or price objective for that company.

Copyright and General Information:

Copyright 2024 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public inform

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies. Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information

